ArticleFrontiers in pharmacology2025
High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.Journal of orthopaedic surgery and research · 2026Article
- Intra-Individual Variability of Vancomycin Trough Concentrations Before and After Implementation of a Standardized Operating Procedure in Orthopedic Inpatients.Antibiotics (Basel, Switzerland) · 2026Article
- Implementing a Standard Operating Procedure Is Associated with Improved Vancomycin Target Attainment in Bone and Joint Infections: A Pre-Post Study.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Current guidelines recommend vancomycin concentrations of 10-20 μg/mL for most infections, with higher levels (15-20 μg/mL) suggested for severe cases. However, evidence supporting these recommendations in periprosthetic joint infection (PJI) is limited. This study aims to evaluate the impact of different vancomycin concentration ranges (10-15 vs. 15-20 μg/mL) on the safety and effectiveness in PJI population. Methods: This retrospective study included 37 patients with vancomycin Therapeutic Drug Monitoring due to periprosthetic joint infection. Patients were categorized into two groups according to vancomycin concentrations, low concentration group (10-15 μg/mL) and high concentration group (15-20 μg/mL). Patients were followed up for at least 2 years. The long term clinical outcomes, inflammatory markers, as well as adverse events were compared. A physiologically based pharmacokinetic model was established to compare vancomycin distribution in kidney and bone marrow between the two groups. Results: There were 23 (62.16%) patients classified as the HC group and 14 (37.84%) as the LC group. The average steady-state trough concentration (Css) in the HC group was 17.74 μg/mL, and in the LC group was 12.11 μg/mL. At the end of follow-up, two patients (5.40%) in the HC group had died, and one (2.7%) was readmitted for joint fusion due to recurrent infections, whereas no deaths or readmissions occurred in the LC group. However, no significant differences were identified. Similar improvements from baseline were observed across WOMAC, Harris, HSS, and SF-12 scores between the groups. The synovial white blood cell (WBC) count was significantly lower in the HC group compared to the LC group (5,481 vs. 7,106/μL, Conclusion: Maintaining vancomycin concentrations of 15-20 μg/mL is associated with better infection control for PJI patients who present with higher synovial WBC account, without compromising patient safety, joint function, or long-term quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.